Heron Therapeutics Inc (NASDAQ:HRTX) VP Kimberly Manhard sold 7,584 shares of the business’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $20.00, for a total value of $151,680.00. Following the completion of the transaction, the vice president now directly owns 7,584 shares of the company’s stock, valued at approximately $151,680. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Shares of Heron Therapeutics Inc (NASDAQ HRTX) opened at $21.40 on Monday. Heron Therapeutics Inc has a 52-week low of $12.25 and a 52-week high of $22.00. The company has a market cap of $1,382.44, a PE ratio of -5.65 and a beta of 2.13. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.02 and a current ratio of 2.12.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.10. The firm had revenue of $8.57 million during the quarter, compared to analyst estimates of $8.12 million. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. sell-side analysts expect that Heron Therapeutics Inc will post -3.38 earnings per share for the current fiscal year.

A number of equities analysts have weighed in on the company. Zacks Investment Research lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. Cantor Fitzgerald set a $31.00 price target on shares of Heron Therapeutics and gave the company a “buy” rating in a research report on Friday, January 5th. ValuEngine raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Leerink Swann initiated coverage on shares of Heron Therapeutics in a research report on Tuesday, January 2nd. They set an “outperform” rating and a $22.00 price target for the company. Finally, BidaskClub raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 20th. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $28.82.

Institutional investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc increased its holdings in Heron Therapeutics by 26.6% in the 2nd quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock worth $157,000 after acquiring an additional 2,383 shares in the last quarter. Quantbot Technologies LP increased its holdings in Heron Therapeutics by 2,619.6% in the 2nd quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock worth $172,000 after acquiring an additional 12,024 shares in the last quarter. Trexquant Investment LP purchased a new stake in Heron Therapeutics in the 3rd quarter worth approximately $206,000. Jane Street Group LLC purchased a new stake in Heron Therapeutics in the 3rd quarter worth approximately $223,000. Finally, HighTower Advisors LLC increased its holdings in Heron Therapeutics by 11.4% in the 2nd quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock worth $231,000 after acquiring an additional 1,700 shares in the last quarter. 98.21% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.dailypolitical.com/2018/01/15/heron-therapeutics-inc-hrtx-vp-kimberly-manhard-sells-7584-shares.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.